CA125单克隆抗体治疗卵巢癌的研究进展

被引：5

作者：

吴嘉涵

鹿欣

机构：

[1] 复旦大学附属妇产科医院

来源：

国际妇产科学杂志 | 2009年 / 36卷 / 01期

关键词：

卵巢癌; CA125; 单克隆抗体; 生物治疗; 载体; 靶向诱导;

D O I：

暂无

中图分类号：

R737.31 [卵巢肿瘤];

学科分类号：

摘要：

随着生物化学、基因学、免疫学及相关学科的发展,CA125单克隆抗体治疗可望成为治疗恶性肿瘤的方法之一。目前CA125单克隆抗体治疗卵巢癌的实验与临床研究已取得较大进展,给卵巢癌特别是术后复发及化疗耐药患者的治疗带来新的希望。卵巢癌CA125单克隆抗体治疗主要有介导人体免疫应答和靶向性载体诱导等。综述近几年卵巢癌CA125单克隆抗体治疗的研究进展。

引用

页码：72 / 74

页数：3

共 5 条

[1] Transient human anti-mouse antibodies (HAMA) interference in CA 125 measurements during monitoring of ovarian cancer patients treated with murine monoclonal antibody
Oei, Angele L. M.
Sweep, Fred C. G. J.
Massuger, Leon F. A. G.
Olthaar, Andre J.
Thomas, Chris M. G.
[J]. GYNECOLOGIC ONCOLOGY, 2008, 109 (02) : 199 - 202
[2] Design of a bifunctional fusion protein for ovarian cancer drug delivery: Single-chain anti-CA125 core-streptavidin fusion protein[J] . Welson Wen-Shang Wang,Dipankar Das,Stephen A. McQuarrie,Mavanur R. Suresh.European Journal of Pharmaceutics and Biopharmaceutics . 2007 (3)
[3] Biotin carboxyl carrier protein co-purifies as a contaminant in core-streptavidin preparations
Wang, WWS
Das, D
Suresh, MR
[J]. MOLECULAR BIOTECHNOLOGY, 2005, 31 (01) : 29 - 40
[4] Constructs of biotin mimetic peptide with CC49 single-chain Fv designed for tumor pretargeting
Pavlinkova, G
Batra, SK
Colcher, D
Booth, BJM
Baranowska-Kortylewicz, J
[J]. PEPTIDES, 2003, 24 (03) : 353 - 362
[5] A three-step strategy for targeting drug carriers to human ovarian carcinoma cells in vitro
Xiao, Z
McQuarrie, SA
Suresh, MR
Mercer, JR
Gupta, S
Miller, GG
[J]. JOURNAL OF BIOTECHNOLOGY, 2002, 94 (02) : 171 - 184

← 1 →